The role of urinary peptidomics in kidney disease research

Klein, J., Bascands, J.-L., Mischak, H. and Schanstra, J. P. (2016) The role of urinary peptidomics in kidney disease research. Kidney International, 89(3), pp. 539-545. (doi: 10.1016/j.kint.2015.10.010) (PMID:26880450)

Full text not currently available from Enlighten.


Urinary peptidomics focuses on endogenous urinary peptide content. Many studies now show the usefulness of this approach for the discovery and validation of biomarkers in kidney diseases that are as varied as chronic kidney disease, acute kidney injury, congenital anomalies of the kidney and the urinary tract, and polycystic kidney disease. Most studies focus on chronic kidney disease and demonstrate that urinary peptidome analysis can substantially contribute to early detection and stratification of patients with chronic kidney disease. A number of multicenter studies are ongoing that aim further validation in a clinical setting and broaden the applicability of urinary peptides. The association of urinary peptides with kidney disease also starts to deliver information on the pathophysiology of kidney disease with emphasis on extracellular matrix remodeling. Bioinformatic peptide centric tools have been developed that allow to model the changes in protease activity involved in kidney disease, based on the urinary peptidome content. A novel application of urinary peptidome analysis is the back-translation of results obtained in humans to animals for animal model validation and improvement of readout in these preclinical models. In conclusion, urinary peptidomics not only contribute to detection and stratification of kidney disease in the clinic, but might also create a new impulse in drug discovery through better insight in the pathophysiology of disease and optimized translatability of animal models.

Item Type:Articles
Additional Information:JK, JLB, and JPS acknowledge support from Institut National de la Santé et de la Recherche Médicale and Agence Nationale de la Recherche (grant IND2N, ANR-12-BSV1-0035-01), and all authors acknowledge support from the European Uremic Toxin Work Group and a number of European projects including Clinical and system –omics for the identification of the MOlecular DEterminants of established Chronic Kidney Disease (iMODE-CKD, PEOPLE-ITN-GA- 2013-608332), European consortium for high-throughput research in rare kidney diseases (EURenOmics, GA2012-305608), Biomarkers of renal graft injuries in kidney allograft recipients (Biomargin, FP7-HEALTH-2012-INNOVATION-1- 305499), and Systems biology to identify molecular targets for vascular disease (Sysvasc, F7-Health-2013-innovation-1, 603288).
Glasgow Author(s) Enlighten ID:Mischak, Professor Harald
Authors: Klein, J., Bascands, J.-L., Mischak, H., and Schanstra, J. P.
College/School:College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
Journal Name:Kidney International
ISSN (Online):1523-1755

University Staff: Request a correction | Enlighten Editors: Update this record